This technology provides improved processes for production and purification of nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be employed as oncolytic agents. Some of the improved processes relate to improved processes for producing viral DNA template.
Researchers at the National Institutes of Health have identified a collection of TCRs that specifically target mutated KRAS antigen. These TCRs exclusively recognize the G12D or G12V variants of mutated KRAS, which are common hotspot driver mutations expressed by a variety of epithelial cancers, including pancreatic, colorectal and lung cancer. The mutated KRAS variants are recognized by the TCRs in the context of HLA-A*11:01 or HLA-C*08:02. These TCRs can be used for a variety of experimental therapeutic, diagnostic and research applications.
Novel thalidomide analogs and their use as immunomodulatory agents are disclosed in this invention by scientists at the National Institute on Aging (NIA). These therapeutic compounds could reduce chronic systemic and central nervous system inflammation. The NIA seeks licensing or co-development partners to commercialize this technology.
The National Institutes of Health, through The National Institutes of Health - Clinical Center (NIH-CC) and the National Heart Lung and Blood Institute (NHLBI), seeks licensing and/or co-development partners for a nitric oxide cream for the treatment of ulcers associated with sickle cell disease.
Researchers at the National Cancer Institute (NCI) have developed a novel method enabling rapid, GMP-compliant manufacture of retroviral vectors encoding anti-tumor T cell receptors (TCRs). T cells engineered through the use of these vectors to express tumor-reactive TCRs will be useful in adoptive cell immunotherapy for the treatment of cancer. Researchers at the NCI seek licensing and/or co-development research collaborations for this invention.
To improve the transduction efficiency the inventors at the National Eye Institute (NEI) have developed a novel, non-invasive approach of applying electric current in combination with a gene therapy vector. This minimally invasive strategy significantly improves the transduction efficiency of AAV vectors in the mouse retina. This represents an improved method for restoring high levels of RS1 expression in the retina of X-linked retinoschisis (XLRS) patients. The NEI seeks a licensing and/or co-development partner to commercialize its AAV-RS1 Gene Therapy for XLRS.
Scientists at the National Cancer Institute developed a method to identify T cells that specifically recognize immunogenic mutations expressed only by cancer cells. NCI seeks parties interested in collaborative research to co-develop or license T-cell therapy against cancer mutations